RxDoctor Payments Data

Debra Graetz, MD

Family Medicine · Traverse City, MINPI 1104963115

Payments from drug & device makers

$3,759in general payments, 2019–2025

Across 176 payments — averaging $21.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$835
  • GSK$713
  • AbbVie$562
  • Lilly USA, LLC$257
  • Pfizer$253
  • Si-bone, Inc.$161
  • plus $979 from 16 others

What the payments were for

  • Food & beverage$3,69998%
  • Education$602%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,759 in reported general payments places this provider in the 85th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$39,213
Medicare patients
110
Services billed
720

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide28$44,137
MounjaroTirzepatide33$33,242
EliquisApixaban27$31,657
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$23,214
MyrbetriqMirabegron16$13,399
Atorvastatin Calcium344$5,099
Levothyroxine Sodium235$3,993
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$3,505
Losartan Potassium209$3,177
Fluticasone-SalmeterolFluticasone Propion/Salmeterol17$3,039
Metoprolol Succinate116$2,415
Albuterol Sulfate HfaAlbuterol Sulfate41$2,029
Lisinopril148$1,722
Omeprazole95$1,709
Tamsulosin Hcl67$1,604

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$835$44,13728 claims
Lilly USA, LLCMounjaro$257$33,24233 claims
PfizerEliquis$253$31,65727 claims
GSKTrelegy Ellipta$713$23,21423 claims
Astellas Pharma US IncMyrbetriq$153$13,39916 claims
AbbVieSynthroid$562$51911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Traverse City

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →